Patents Represented by Attorney, Agent or Law Firm Michael G. Sullivan
  • Patent number: 6045806
    Abstract: The invention is directed to a vaccine comprising Babesia canis antigens from a strain of Babesia canis rossi and another Babesia canis subspecies.Such a vaccine gives both homologous protection, and heterologous protection to infection with strains other than those of which the antigens have been isolated.Preferably the antigens are soluble antigens which can be harvested from the supernatant of a culture of Babesia parasites.
    Type: Grant
    Filed: July 5, 1995
    Date of Patent: April 4, 2000
    Assignee: Akzo Nobel N.V.
    Inventor: Theodorus Petrus Maria Schetters
  • Patent number: 6037339
    Abstract: A C-11 substituted steroid and a method of use of a C-11 substituted steroid to treat osteoporosis.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: March 14, 2000
    Assignee: Akzo Nobel N.V.
    Inventors: Hubert Jan Jozef Loozen, Lodewijk Pieter Cornelis Schot, Jane Margretha Lena van der Werf-Pieters
  • Patent number: 6033886
    Abstract: The present invention provides the generation of infectious replicating non-segmented negative-stranded RNA virus, entirely from cloned cDNA. This process offers the possibility to introduce mutations into the virus genome by means of recombinant DNA techniques.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: March 7, 2000
    Inventor: Karl Klaus Conzelmann
  • Patent number: 6030772
    Abstract: Neutralizing antibodies against HIV infection are provided. The antibodies are reactive with cryptic epitopes on gp120 and/or CD4 induced by the formation of immunogenic complexes comprising gp120 covalently bonded to CD4 or to succinyl concanvalin A.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: February 29, 2000
    Assignee: Akzo Nobel N.V.
    Inventors: Anthony L. Devico, Ranajit Pal, Mangalasseril G. Sarngadharan
  • Patent number: 6020170
    Abstract: The present invention relates to an efficient method of producing monoclonal antibodies against surface antigens of cells and viruses. The method accommodates for antigens which are present in only relatively small amounts, or antigens of which only very small amounts are available or antigens which easily lose their in vivo conformation. Thus the method according to the invention comprises a series of steps, comprising a step in which B-cells from a mammal injected with surface antigen-comprising material are enriched with respect to the relative number of specific B-cells and a step which comprises a small-scale fusion technique.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: February 1, 2000
    Assignee: Akzo Nobel, N.V.
    Inventor: Petrus Gerardus Antonius Steenbakkers
  • Patent number: 6010847
    Abstract: The sensitivity and reliability (robustness) of CMV mRNA detection is greatly dependent on the selection of suitable oligonucleotides for amplification, since there is sequence variation among strains of CMV potentially in every region of the genome. The present invention is concerned with oligonucleotides that can be used in the amplification and detection of human Cytomegalovirus (HCMV) mRNA. These novel oligonucleotides show an improved sensitivity and robustness of CMV mRNA detection if compared with known sequences when used in amplification and detection. Furthermore a method for the diagnosis of HCMV disease is provided.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: January 4, 2000
    Assignee: Akzo Nobel N.V.
    Inventors: Peter Theodorus Gerardus Sillikens, Eveline Catharina Anna Clasina Timmermans
  • Patent number: 6001348
    Abstract: The present invention provides NAD-independent Mycoplasma synoviae of strain MS1. The invention also refers to microbiological cultures comprising Mycoplasma synoviae of this strain. Next to this, the invention refers to live vaccines derived from these strains, for the protection of poultry against Mycoplasma synoviae infection. Furthermore, the invention provides methods for the preparation of such vaccines. Also, the use of NAD-independent Mycoplasma synoviae strains for the preparation of live vaccines for the protection of poultry against Mycoplasma synoviae infection is disclosed.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: December 14, 1999
    Assignee: Akzo Nobel N.V.
    Inventor: Maarten Hendrik Witvliet
  • Patent number: 5994366
    Abstract: The present invention relates to certain tetrahydroimidazo[2,1-a]isoquinoline derivatives according to formula I wherein X is a group (A) or (B) ##STR1## R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each represent one or more substituents selected from hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.4-6 cycloalkenyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and halogen;R.sup.4, R.sup.5, R.sup.6 and R.sup.7, which may be the same or different, are each selected from hydrogen, C.sub.1-6 alkoxyC.sub.1-6 alkyl, C.sub.4-6 cycloalkenyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl and C.sub.1-6 alkyl; n is 1 or 2; or a pharmaceutically acceptable salt or solvate thereof, to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of depression.
    Type: Grant
    Filed: June 25, 1998
    Date of Patent: November 30, 1999
    Assignee: Akzo Nobel NV
    Inventors: Dirk Leysen, Gerardus Stephanus Franciscus Ruigt
  • Patent number: 5968732
    Abstract: An isothermal transcription based amplification assay for dengue virus RNA uses primer combinations for sequences within the envelope gene or the 3' non-coding region of the virus and a probe. Probes may be specific for a serotype of dengue virus.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: October 19, 1999
    Assignee: Akzo Nobel, N.V.
    Inventors: Joseph W. Romano, Eun Mi Lee, Gregory J. Hurteau
  • Patent number: 5935974
    Abstract: The invention relates to a diphenylmethylene piperidine derivative of the formula ##STR1## wherein n is 1 or 2; or a pharmaceutically acceptable salt thereof, for use in therapy, in particular for use as a dopamine antagonist for the treatment or prophylaxis of psychotic disorders.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: August 10, 1999
    Assignee: Akzo Nobel, N.V.
    Inventors: Duncan Robertson Rae, David Robert Jaap
  • Patent number: 5876935
    Abstract: A luminescent specific binding assay method is used for detecting an analyte in whole blood. The assay is a heterogeneous sandwich or competitive assay in which a first binding reagent is labeled with a luminescent photoprotein and an immobilized second binding reagent serves as a capture reagent. The luminescent photoprotein, upon activation, emits light which may be detected by a luminescence detector. The assay is rapid, sensitive and may be performed on small sample volumes.
    Type: Grant
    Filed: January 8, 1997
    Date of Patent: March 2, 1999
    Assignee: Dade Behring Inc.
    Inventors: Thomas John Pankratz, Richard Wayne Stout